Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Dr Spira Talks Amivantamab Plus Lazertinib for Osimertinib-Relapsed, EGFR+ NSCLC

Alexander Spira, MD PhD, FACP, Virginia Cancer Specialists, discusses the use of amivantamab in combination with lazertinib for the treatment of chemotherapy-naïve patients with osimertinib-relapsed, EGFR+ non-small-cell lung cancer (NSCLC) and potential biomarkers for response, presented at the 2021 ASCO Annual Meeting. 

Advertisement

Advertisement

Advertisement

Advertisement